The halogenated tetrahydro-β-carboline 'TaClo': A progressively-acting neurotoxin

Christine Heim, K. H. Sontag

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


'TaClo', (1-trichloromethyl-1,2,3,4-tetrahydro-β-carboline) which is structurally very similar to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), increases the sensitivity to apomorphine in aging rats after subchronic daily application (0.2 mg/kg i.p.) for 7 weeks. Nine weeks after the last treatment with TaClo, the running speed of the animals during spontaneous nocturnal activity was significantly diminished, and 9 months after the last injection rats developed a pronounced hypersensitivity to apomorphine (0.4 mg/kg s.c.). TaClo, which can be readily produced from endogenous tryptamine and the non-natural aldehyde chloral, appears to be a drug that is able to induce a slowly-developing neurodegenerative process.

Original languageEnglish (US)
Pages (from-to)107-111
Number of pages5
JournalJournal of Neural Transmission, Supplement
Issue number50
StatePublished - Jan 1 1997

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'The halogenated tetrahydro-β-carboline 'TaClo': A progressively-acting neurotoxin'. Together they form a unique fingerprint.

Cite this